SL ‘00 Antagonists in patients with previous poor ovarian response Antagonists in patients with previous poor ovarian response Geoffrey H Trew Consultant.

Slides:



Advertisements
Similar presentations
In Vitro Fertilization
Advertisements

New Developments in Assisted Reproduction
Ovarian Ageing and Fertility
Jisha Rajendran Keay SD et al. BJOG
 OHSS is a serious, potentially life- threatening, iatrogenic complication of “controlled” ovarian stimulation.  To optimize the ovarian response without.
PREVENTION OF MULTIPLES FROM A CLINICIAN’S STANDPOINT Bulent Urman M.D. American Hospital of Istanbul.
‘President’s Medal’ for best medical graduate ‘Dr. B.C Roy’s award’ in 1999 for outstanding contribution towards medicine and field of specialty,
Shahar Kol, Maccabi Health Care Services Rambam Health Care Campus Technion, Israel Institute of Technology.
ART-IVF: the Long and Short of it Professor Ernest Hung Yu NG Department of Obstetrics & Gynaecology The University of Hong Kong.
Elonva in poor responders
Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.
Gonadotrophin-releasing hormone antagonists for assisted reproductive technology in women with poor ovarian response. Subgroup analysis of Cochrane systematic.
Embryo Transfer: Practical Tips to Get Ready for Prime Time
SURGICAL TREATMENT OF PCOS SURGICAL TREATMENT OF PCOS Professor T C LI Professor of Reproductive Medicine & Surgery Sheffield.
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
IVM is ready as a treatment for PCOS patients
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF Jessica B Spencer 1*, Aimee S Browne 1, Susannah D Copland.
Prof.Dr.Tayfun BAĞIŞ 15/05/2013 TJOD. TerminologyAimMethodology Natural cycle IVFSingle oocyteNo medication No luteal support Modified NC IVFSingle.
The uses of antagonist in IVF/ICSI cycle Prof. Dr. Mohamed Said Elmahaishi Lamis IVF Centre Misurata/ Libya 5 th International Congress In Infertility.
Does exogenous LH activity influence the outcome in IVF and not in ICSI cycles? Peter Platteau, Johan Smitz, Carola Albano, Per Sørensen Joan-Carles Arce.
ART Assisted reproductive technology Dithawut Khrutmuang MD.
Infertility New Issues. Yunus Tayob Clinical Lead in Reproductive Medicine and Reproductive Endoscopic Surgery.
MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED INFERTILITY STATE OF THE ART!
TEMPLATE DESIGN © Oocyte donation outcomes at Alpha International Fertility Centre IntroductionResultsConclusions References.
Planning of GnRH antagonist cycles
Treatment Options for Infertility
Dr. Milton Leong Director
The Effect of Bromocriptine-Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: a Randomized Clinical Trial.
The 4th Misurata scientific meeting of infertility Benghazi – Libya 10/10/2008 Dr. Omar A. Elsraiti Consultant of Obst. & Gyn. IVF Centre - Misurata /
IVF - ICSI ÖNCESİ ENDOMETRIOMALAR ÇIKARTILMALI MI? Prof. Dr. Bülent Baysal İ.Ü. İstanbul Tıp Fakültesi.
GNRH-A TRIGGER AND INDIVIDUALIZED LUTEAL PHASE HCG SUPPORT WILL AVOID OHSS IN PCOS PATIENTS. Shahar Kol, IVF Unit Rambam Health Care Campus, and Faculty.
TEMPLATE DESIGN © IMPACT OF SEXUAL ABSTINENCE DURATION ON ICSI OUTCOME May Kew Loke and Pak Seng Wong Sunfert International.
Agonist vs Antagonist Dr. Milton Leong.
How to schedule GnRH antagonist cycles?
Recommended Dosage of GnRH Antagonist is Too High Presented by Dr. Milton Leong, MD DSc(McGill) Director, IVF Centre.
Selecting sperm for ICSI - IMSI Allan Pacey University of Sheffield Sheffield Teaching Hospitals.
ART FOR PCOS-DIFFICULTIES AND SOLUTIONS Dr. Bulent Urman American Hospital, ISTANBUL Assisted Reproduction Unit Koç University, Faculty of Medicine Department.
Dr. Hakan Özörnek EUROFERTIL IVF Center
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
FERTILITY TREATMENT AND IVF TYPES OF TREATMENT & THE PSYCHOLOGICAL EFFECTS.
Georg Griesinger UK-SH, Campus Luebeck Germany. We have a problem…
IVF TROUBLESHOOTING ( Clinical Perspective) Malvin Emeraldi M. Luky, Dianing ASR,Muchsin J Family Fertility Center, RSIA Family Fatmawaty Hospital Jakarta,
Fertility Facts Definition:unprotected sex for one year, not pregnant
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
How IVF Protocols Work to Enhance the Success of IVF: Agonist vs Antagonist Dr Dimitrios Dovas MD Newlife IVF Greece.
Use of GnRH antagonists for IVF
Mohamed Elmahdy MD. Lecturer Obs. Gyn. Alexandria University Egypt
The approach to the PCOS patient undergoing IVF
Dealing with ART failure – what should be the stimulation we offer
To operate or not to operate before IVF
Hormonal profile of the same oocyte donors stimulated with either GnRH antagonist or agonist compared with natural cycles.
Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:
Supplemental Table 2. Reproductive outcomes
The effect of the duration of stimulation on ART outcomes
Antagonists in poor-responder patients
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage.
Ovarian stimulation protocols for IVF: is more better than less?
Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis 
Improvements achieved in an oocyte donation program over a 10-year period: sequential increase in implantation and pregnancy rates and decrease in high-order.
Jyotsna Pundir, Sesh Kamal Sunkara, Tarek El-Toukhy, Yacoub Khalaf 
How to do a study? Prof. P. Devroey.
Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement    Fertility and Sterility  Volume 102,
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Fertility Options Specifically for LGBTQ Patients
A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Fertility and Sterility
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Presentation transcript:

SL ‘00 Antagonists in patients with previous poor ovarian response Antagonists in patients with previous poor ovarian response Geoffrey H Trew Consultant in Reproductive Medicine & Surgery, Hammersmith Hospital Chief of Service, Imperial College NHS Trust London

Poor responders………. Difficult group for ; PatientsPatients StaffStaff ResultsResults

Definitions……. Main ; number of egg < 5, cancelled cyclesMain ; number of egg < 5, cancelled cycles But also a lot of American studies use ; Raised FSH Female age >40 AFC < 5 Endometriosis grade III or IV

Variation The greater the number of protocols there are - the poorer the evidence for any particular one.....

Evidence Based Medicine Archie CochraneArchie Cochrane Do we need evidence ?Do we need evidence ? Why ?Why ? What evidence do we have ?What evidence do we have ?

The evidence Or some of it ……

Best outcome………… But…. There are other important outcomes as well ; Egg collectionEgg collection Embryo transferEmbryo transfer

Agonist v Antagonist Cancellation RatesCancellation Rates Previous agonist cycle cancelledPrevious agonist cycle cancelled New cycle – increased doseNew cycle – increased dose Randomised to either agonist or antagonistRandomised to either agonist or antagonist

Cancellation Rate on following cycle with poor responders Brook…Trew, J Obstet & Gynecol, AntagonistBuserelin % P=0.011

…… A Prospective RCT of microdose leuprolide v ganirelix …… Pilot study - 48 ptsPilot study - 48 pts previous poor response previous poor response … ganirelix appears to be as effective as the microdose protocol and may be a superior choice in terms of cost and convenience… ganirelix appears to be as effective as the microdose protocol and may be a superior choice in terms of cost and convenience Schmidt et al Fertil steril May 2005

Antagonists in IVF poor responders – results of randomised trial Antagonist v standard long ; 60 ptsAntagonist v standard long ; 60 pts Antagonist group ; less drugs P = less drugs P = more eggs P = 0.02more eggs P = 0.02 Fewer cycles cancelledFewer cycles cancelled PR 17% per ET v 7% per ETPR 17% per ET v 7% per ET Marci et al RBM Online Aug 2005

Flexible GnRH Antagonist v flare up GnRH Agonist in poor responders…a RCT 5 or less oocytes with dose = or > 300iu5 or less oocytes with dose = or > 300iu Antagonist (180pts) v flare agonist (90pts)Antagonist (180pts) v flare agonist (90pts) PR ; 12.2% v 4.4%PR ; 12.2% v 4.4% ( p<0.048) Lainas…Kolibianakis, et al : Hum Reprod April 2008

Poor responders Just about every different protocol triedJust about every different protocol tried Different FSH dosesDifferent FSH doses Different Agonist dosesDifferent Agonist doses Antagonists fixed / flexibleAntagonists fixed / flexible Various additives inc LH growth hormone etcVarious additives inc LH growth hormone etc ‘Soft’ / Natural protocols‘Soft’ / Natural protocols Still poor results!Still poor results!

What is your preferred ovarian stimulation regime for “poor responders” ? Clomifene/ gonadotrophin26%Clomifene/ gonadotrophin26% Ultrashort agonist23%Ultrashort agonist23% Short agonist30%Short agonist30% Long agonist17%Long agonist17% Antagonist 58% (Serono Symposia Mtg Athens Dec 2006)

What is your preferred ovarian stimulation dose for “poor responders” 200 iu2%200 iu2% 225 iu4%225 iu4% 300 iu21%300 iu21% 375 iu 9%375 iu 9% 450 iu 47%450 iu 47% > 450 iu15%> 450 iu15%

What should the maximum FSH dose be in poor responders ? “ little or no clinical benefit in doses > 300 iu”“ little or no clinical benefit in doses > 300 iu” “…but costs and side effects were higher”“…but costs and side effects were higher” Siristatidis & Hamilton, J Obstet Gynecol May 2007

Other options Give up / expectant management Give up / expectant management Corrective surgery of underlying problem Corrective surgery of underlying problem Natural cycle IVF Natural cycle IVF IUI - If no significant male factor / tubal factor IUI - If no significant male factor / tubal factor IUI and donor sperm if significant male factor IUI and donor sperm if significant male factor Egg Donation Egg Donation 50% + pregnancy rates 50% + pregnancy rates

Conclusions Difficult group to treatDifficult group to treat Poor pregnancy rates in true poor respondersPoor pregnancy rates in true poor responders Antagonist protocolsAntagonist protocols High dose of FSHHigh dose of FSH

Please ! Do not use antagonists just for poor responders use them for all groups of patients !!Do not use antagonists just for poor responders use them for all groups of patients !! Results are goodResults are good Patients love them !Patients love them !

Thank You !